32 results about "Morphine tolerance" patented technology

The invention discloses an endogenous long-chain non-coding RNA MRAK049966 and its application. Specifically, it refers to the application of the long-chain non-coding RNA MRAK049966 in the preparation of drugs for treating or alleviating chronic pain. The drug for treating or relieving chronic pain refers to the drug for suppressing morphine tolerance. The long non-coding RNA MRAK049966 is a novel long non-coding RNA reported for the first time, and has been confirmed to be associated with morphine tolerance. The invention provides a new approach for treating or relieving chronic pain, slowing down or reversing the formation of morphine tolerance, and has important medical significance.

The invention discloses an anti-opioid peptide, and antagonistic peptide and the application thereof. The anti-opioid peptide is one of the amino acid residue sequences: 1) SEQ ID No.1 in the sequence list; 2) SEQ ID NO.3-5; 3) the peptides derive from the amino acid residue sequences of SEQ ID NO.1 and SEQ ID NO.3-5 in the sequence list that are substituted by, lost by or added with one to ten amino acid residue sequences, with antagonistic morphia effects and harm resistance. The antagonistic peptide is one of the amino acid residue sequences: 1) SEQ ID NO.9-11 in the sequence list; 2) the amino acid residue sequences of the SEQ ID NO.9-11 in the sequence list are substituted or lost by one to ten amino acid residue sequences, or opypeptide provided with functions of intensified analgesia, reversing morphia resistance and / or releasing or removing withdrawal symptoms is added. The anti-opioid peptide and the active segments thereof and antagonistic peptide of the invention play important roles in the preparation fields of medical science and anti-additive drugs, and have a promising prospect.

The invention discloses a polypeptide with a morphine tolerance and side effect relieving function and an application of the polypeptide. The polypeptide is named as TAT-mu1 and as shown in following(1) or (2): (1) a polypeptide of a (12-58) amino acid residue of an amino acid sequence as shown in SEQ ID NO:1; (2) a polypeptide of an amino acid sequence as shown in SEQ ID NO:1. The polypeptide TAT-mu1 comes from a mu opioid receptor carboxyl terminal, the TAT-mu1 and the mu opioid receptor carboxyl terminal can be competitively phosphorylated by G protein-coupled receptor kinase when morphine acts on a mu opioid receptor, the phosphorylated TAT-mu1 can be combined with beta-arrestin2, and interaction of the mu opioid receptor and the beta-arrestin2 is interfered, so that beta-arrestin2 mediated morphine tolerance and side effect symptoms are relieved. The polypeptide TAT-mu1 has clinical application potential in prevention and treatment of morphine tolerance, side effects and thelike.

The invention discloses an anti-opioid peptide, antagonist peptide and application thereof. The anti-opioid peptide is polypeptide formed by the way that one of the following amino acid residue sequences: 1) SEQ ID NO: 1 in the sequence table; 2) SEQ ID NO: 3-5; 3) amino acid residue sequences of SEQ ID NO: 1, SEQ ID NO: 3-5 in the sequence table are subject to substitution, deletion or addition of one to ten amino acid residues to have antagonist morphine anti-harm effect. The antagonist peptide thereof is polypeptide formed by the way that one of the following amino acid residue sequences: 1) SEQ ID NO: 9-11 in the sequence table; 2) amino acid residue sequences of SEQ ID NO: 9-11 in the sequence table is subject to substitution, deletion or addition of one to ten amino acid residues to have effects of enhancing morphine analgesia, reversing morphine tolerance and / or reducing or eliminating abstinence symptom. The anti-opioid peptide and active segment thereof and antagonist peptide can play important role in the medicinal and rehabilitation medicine preparation field and has wide application prospect.

The invention discloses an anti-opioid peptide, an antagonist peptide thereof and use thereof. The anti-opioid peptide has an amino acid residue sequence represented by: 1) an amino acid residue sequence SEQ ID No.1 in a sequence table; 2) an amino acid residue sequence SEQ ID No.3-5; and 3) an amino acid residue sequence obtained by substituting, losing or adding 1 to 10 amino acid residues in the amino acid residue sequence SEQ ID No.1 and the amino acid residue sequence SEQ ID No.3-5 in the sequence table. The anti-opioid peptide is a polypeptide having the antinociptive function of antagonist morphine. The antagonist peptide is has amino acid residue sequence represented by: 1) an amino acid residue sequence SEQ ID No.9-11 in a sequence table; and 2) an amino acid residue sequence obtained by substituting, losing or adding 1 to 10 amino acid residues in the amino acid residue sequence SEQ ID No.9-11 in the sequence table. The antagonist peptide is a polypeptide having the functions of strengthening the pain-relieving effect of morphine, reversing morphine tolerance and / or weakening or eliminating abstinence syndrome. The anti-opioid peptide, the active fragment thereof and the antagonist peptide are expected to play significant roles in the field of medicine and the field of the preparation of medicaments for treating drug addition and have wide application range.

The invention discloses an anti-opioid peptide, as well as an antagonistic peptide and application thereof. The anti-opioid peptide is one of the following amino acid residue sequences: (1) SEQ ID NO:1 in a sequence table and (2) a polypeptide which is obtained by substituting, deleting or adding 1-10 amino acid residues on an amino acid residue sequence of SEQ ID NO:1 in the sequence table and has an antinociceptic effect on antagonistic morphine. The antagonistic peptide is one of the following amino acid residue sequences: (1) SEQ ID NO:5-7 in a sequence table and (2) a polypeptide which is obtained by substituting, deleting or adding 1-10 amino acid residues on an amino acid residue sequence of SEQ ID NO:5-7 in the sequence table and has the effects of enhancing morphine analgesia, reversing morphine tolerance and / or weakening or eliminating abstinence syndromes. The anti-opioid peptide as well as an active segment and the antagonistic peptide thereof play an important role in thefield of preparation of medical and medicament abstinence medicaments, and have wide application prospects.

The invention discloses anti-opioid peptide, and antagonistic peptide and application thereof. The anti-opioid peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:1 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:1 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effect of resisting morphine damages. The antagonistic peptide has one of the following amino acid residue sequences: 1) SEQ ID NO:5-7 in a sequence table; and 2) the amino acid residue sequence shown as the SEQ ID NO:5-7 in the sequence table is replaced and deleted by 1 to 10 amino acid residues or added with polypeptide with the effects of enhancing morphine analgesia, reversing morphine tolerance and / or weakening or eliminating abstinence syndromes. The anti-opioid peptide and an active segment and the antagonistic peptide thereof exert an important effect in the field of preparation of medicinal and drug treatment medicaments and have wide application prospects.

The invention provides an application of endogenic non-coding small RNA miR-873, particularly an application of the miR-873 in drugs for treating or alleviating chronic pain and morphine tolerance. In addition, the endogenic non-coding small RNA miR-873 also can be used in the preparation of preparations for regulating the A20 gene and regulating preparations for the proinflammatory factor TNF Alpha released by the spinal cord under the condition of morphine tolerance. The invention proves that since the miR-873 can regulate the TNF alpha-induced protein-3 (A20) to participate in the development of morphine tolerance, an important foundation is laid for the application of the miR-873 in drugs for treating or alleviating chronic pain and morphine tolerance.